The most important asset of any company is its personnel. We have been successful in attracting several key executives who bring a tremendous track record of success in the biopharmaceutical industry. From drug development, clinical trials and regulatory submission to financial and strategic planning, InMed’s team is well poised to face the complex challenges specific to our industry.

One of the most evident indicators of our evolution over the past year is reflected in the vastly improved financial position of the Company. We have successfully attracted over $10M in investments to fund our corporate and scientific development. The latest $5.75M was backed by two Investment Banks that have provided significant leadership in our specialty sector, Canaccord Genuity and ROTH Capital Markets. Additionally, we have retained KPMG as our auditors, which will be of significant importance as we continue to evolve.

InMed has made considerable advances and continued expansion upon the solid scientific foundation established by Dr. Sazzad Hossain, InMed’s Chief Scientific Officer. His innovative bioinformatics approach to targeting cannabinoids to specific diseases, and then enabling the biosynthesis of these cannabinoids for development into pharmaceutical drugs, continues to serve as the scientific basis for the company.

One significant accomplishment to note is the InMed-UBC study (NR- Oct.24, 2017). This study is what we believe to be the first ever to report the use of a cannabinoid nanoparticle hydrogel for drug delivery into the eye, resulting in enhanced drug uptake via the cornea and lens. This study further validates the Company’s capacity to conduct a wide spectrum of drug development activities, including: 

• biosynthesis of a cannabinoid using a proprietary E. coli-based system;
• packaging the cannabinoid as a nanoparticle;
• formulation of a cannabinoid drug candidate into a novel, tissue specific delivery formulation;
• confirmation of drug delivery and diffusion into a target tissue; and
• validation and measurement of key surrogate efficacy parameters in an ex vivo model.

Additionally, we have advanced our products into final formulation stage while making significant progress with the biosynthesis program. Our collaborations with Dr. Vikramaditya Yadav and his team of researchers at the University of British Columbia continue to bring forth scientific innovation and support the Company’s many drug development programs.